Survival prognostic factors for differentiated thyroid cancer patients with pulmonary metastases: A systematic review and meta-analysis

被引:5
|
作者
Zhao, Hao [1 ]
Liu, Chun-Hao [1 ]
Cao, Yue [1 ]
Zhang, Li-Yang [1 ]
Zhao, Ya [1 ]
Liu, Yue-Wu [1 ]
Liu, Hong-Feng [1 ]
Lin, Yan-Song [1 ,2 ]
Li, Xiao-Yi [1 ]
机构
[1] Chinese Acad Med Sci & Peking Union Med Coll, Peking Union Med Coll Hosp, Dept Gen Surg, Beijing, Peoples R China
[2] Chinese Acad Med Sci & Peking Union Med Coll, Peking Union Med Coll Hosp, Dept Nucl Med, Beijing, Peoples R China
来源
FRONTIERS IN ONCOLOGY | 2022年 / 12卷
关键词
differentiated thyroid cancer; pulmonary metastases; prognosis; meta-analysis; systematic review; ANTITHYROGLOBULIN ANTIBODY-LEVELS; THYROGLOBULIN-NEGATIVE PATIENTS; TERT PROMOTER MUTATIONS; LYMPH-NODE METASTASIS; DISTANT METASTASES; LUNG METASTASES; BONE METASTASES; DOUBLING-TIME; EXTRATHYROID EXTENSION; MULTIVARIATE-ANALYSIS;
D O I
10.3389/fonc.2022.990154
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: The prognostic factors for differentiated thyroid cancer (DTC) patients with pulmonary metastases (PM) remain scantly identified and analyzed. Therefore, this systematic review and meta-analysis were performed to identify and summarize the prognostic factors in adult DTC patients with PM to help distinguish patients with different prognoses and inform the rational treatment regimens. Method: We performed a comprehensive search of the relevant studies published in the Cochrane Library, PubMed, Scopus, Embase, Wanfang database, VIP database, China National Knowledge Infrastructure, and Google Scholar from their inception until February 2021. The pooled hazard ratios (HR) for overall survival and/or progression-free survival (PFS) with 95% confidence intervals were applied to evaluate and identify the potential prognostic factors. Pooled OS at different time points were also calculated for the available data. A random-effects model was used in the meta-analysis. Results: The review and meta-analysis included 21 studies comprising 2722 DTC patients with PM. The prognostic factors for poor OS were: age over 40 years (HR=7.21, 95% confidence interval [CI] 1.52-34.10, P=0.01, N=788), age over 45 years (HR=2.18, 95% CI 1.26-3.77, P < 0.01, N=601), male gender (HR=1.01, 95% CI 1.01-1.19, P=0.03, N=1396), follicular subtype of thyroid cancer (HR=1.63, 95% CI 1.36-1.96, P < 0.01, N=2110), iodine non-avidity (HR=3.10, 95% CI 1.79-5.37, P < 0.01, N=646), and metastases to other organs (HR=3.18, 95% CI 2.43-4.16, P < 0.01, N=1713). Factors associated with poor PFS included age over 45 years (HR=3.85, 95% CI 1.29-11.47, P < 0.01, N=306), male gender (HR=1.36, 95% CI 1.06-1.75, P=0.02, N=546), iodine non-avidity (HR=2.93, 95% CI 2.18-3.95, P < 0.01, N=395), pulmonary metastatic nodule size over 10mm (HR=2.56, 95% CI 2.02-3.24, P < 0.01, N=513), and extra-thyroidal invasion (HR=2.05, 95% CI 1.15-3.67, P=0.02, N=271). The pooled 1, 3, 5, 10, 15, and 20-years OS were 95.24%, 88.46%, 78.36%, 64.86%, 56.57%, and 51.03%, respectively. Conclusions: This review and meta-analysis identified the prognostic factors of DTC patients with PM. Notably, FTC, metastases to other organs, and iodine non-avidity were particularly associated with poor prognosis. The identified prognostic factors will help guide the clinical management of DTC patients with PM.
引用
收藏
页数:13
相关论文
共 50 条
  • [41] Risk Factors for Brain Metastases in Patients With Small Cell Lung Cancer: A Systematic Review and Meta-Analysis
    Zeng, Haiyan
    Zheng, Danyang
    Witlox, Willem J. A.
    Levy, Antonin
    Traverso, Alberto
    Kong, Feng-Ming
    Houben, Ruud
    De Ruysscher, Dirk K. M.
    Hendriks, Lizza E. L.
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [42] Risk of primary breast cancer in patients with differentiated thyroid cancer undergoing radioactive iodine therapy: a systematic review and meta-analysis
    Nappi, Carmela
    Klain, Michele
    Cantoni, Valeria
    Green, Roberta
    Piscopo, Leandra
    Volpe, Fabio
    Maurea, Simone
    Petretta, Mario
    Cuocolo, Alberto
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2022, 49 (05) : 1630 - 1639
  • [43] Risk of primary breast cancer in patients with differentiated thyroid cancer undergoing radioactive iodine therapy: a systematic review and meta-analysis
    Carmela Nappi
    Michele Klain
    Valeria Cantoni
    Roberta Green
    Leandra Piscopo
    Fabio Volpe
    Simone Maurea
    Mario Petretta
    Alberto Cuocolo
    European Journal of Nuclear Medicine and Molecular Imaging, 2022, 49 : 1630 - 1639
  • [44] Risk of Adverse Cardiovascular Outcomes in Differentiated Thyroid Cancer Survivors: A Systematic Review and Meta-Analysis
    Qiang, Judy K. K.
    Alwithenani, Raad
    Uleryk, Elizabeth
    Ezzat, Shereen
    Lipscombe, Lorraine L. L.
    Sawka, Anna M. M.
    THYROID, 2023, 33 (02) : 192 - 202
  • [45] Histopathological prognostic factors for colorectal liver metastases: A systematic review and meta-analysis of observational studies
    Cavalcante de Oliveira, Cassio Virgilio
    Fonseca, Gilton Marques
    Pirola Kruger, Jaime Arthur
    de Mello, Evandro Sobroza
    Coelho, Fabricio Ferreira
    Herman, Paulo
    HISTOLOGY AND HISTOPATHOLOGY, 2021, 36 (02) : 159 - 181
  • [46] The effect of BMI on survival outcome of breast cancer patients: a systematic review and meta-analysis
    Kong, Yu-huan
    Huang, Jing-yi
    Ding, Ye
    Chen, Shu-hua
    Li, Qiu-shuang
    Xiong, Yang
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2025, 27 (02) : 403 - 416
  • [47] Is thyroglobulin a reliable biomarker of differentiated thyroid cancer in patients treated by lobectomy? A systematic review and meta-analysis
    Giovanella, Luca
    Ceriani, Luca
    Garo, Maria Luisa
    CLINICAL CHEMISTRY AND LABORATORY MEDICINE, 2022, 60 (07) : 1091 - 1100
  • [48] Association of the Cumulative Dose of Radioactive Iodine Therapy With Overall Survival in Patients With Differentiated Thyroid Cancer and Pulmonary Metastases
    Yang, Jing
    Zheng, Rong
    Liang, Meng
    Jia, Yingying
    Lin, Lin
    Gang, Jianhua
    Chen, Shengzu
    Li, Ye-Xiong
    FRONTIERS IN ONCOLOGY, 2019, 9
  • [49] Effect of Thyroid-Stimulating Hormone Suppression Therapy on Cardiac Structure and Function in Patients With Differentiated Thyroid Cancer After Thyroidectomy: A Systematic Review and Meta-Analysis
    Zhang, Hongling
    Yang, Yanlong
    Gao, Cuixia
    Tian, Limin
    ENDOCRINE PRACTICE, 2024, 30 (02) : 177 - 186
  • [50] Risk of suicide in patients with thyroid cancer: protocol for a systematic review and meta-analysis
    Li, Chen
    Zhang, Mengmeng
    Wang, Quan
    Jiang, Kewei
    Ye, Yingjiang
    BMJ OPEN, 2024, 14 (01):